$FOLD

BioMarin Pharmaceutical presented its growth strategy during a recent conference, emphasizing the progress of its VOXZOGO drug for achondroplasia treatment and outlining a new deal with Amicus Therapeutics. The company reported positive data regarding VOXZOGO, which is expected to generate significant revenue. The announcement has sparked investor interest, showcasing BioMarin's commitment to innovation and partnership in the rare disease space. Furthermore, the Amicus deal is perceived as a strategic move to bolster their market position. Overall, this news signals a promising outlook for BioMarin's future growth potential.